Qulipta

Chemical Nameatogepant
Dosage FormTablet (oral; 10 mg, 30 mg, 60 mg)
Drug ClassCalcitonin gene-related peptide receptor antagonists
SystemNervous
CompanyAbbVie
Approval Year2021

Indication

  • For the preventive treatment of episodic migraine in adults.
Document TitleYearSource
Qulipta (atogepant) Prescribing Information.2021AbbVie Inc., North Chicago, IL
Drug updated on 7/5/2023

More on this drug: Clinical Trials